Get the Stockscreener App
61.66
1.56%
-1.33
Haemonetics Corp stock is traded at $61.66, with a volume of 595.16K.
It is down -1.56% in the last 24 hours and down -20.22% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$62.99
Open:
$61.93
24h Volume:
595.16K
Relative Volume:
0.86
Market Cap:
$3.16B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
25.59
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
-10.20%
1M Performance:
-20.22%
6M Performance:
-27.67%
1Y Performance:
-19.59%
1-Day Range:
$61.60
$63.97
1-Week Range:
$61.43
$71.51
52-Week Range:
$61.43
$97.97
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
61.67 | 3.16B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ISRG
Intuitive Surgical Inc
|
588.10 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.28 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
90.84 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
237.37 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
328.58 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Needham & Company LLC Lowers Haemonetics (NYSE:HAE) Price Target to $108.00 - Armenian Reporter
Haemonetics Corporation (NYSE:HAE) Q3 2025 Earnings Call Transcript - Insider Monkey
Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Haemonetics (NYSE:HAE) Shares Gap Down After Earnings Miss - Defense World
Haemonetics Corp (HAE) Q3 2025 Earnings Call Highlights: Strong Hospital Growth Amid Plasma Revenue Challenges - GuruFocus.com
Haemonetics Corp (HAE) Q3 2025 Earnings Call Highlights: Strong Hospital Growth Amid Plasma ... - Yahoo Finance
Boston Trust Walden Corp Has $71.50 Million Position in Haemonetics Co. (NYSE:HAE) - MarketBeat
Earnings call transcript: Haemonetics Q3 2024 sees EPS beat, stock drops - MSN
Haemonetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 28, 2024 - Marketscreener.com
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Haemonetics (NYSE:HAE) Issues FY 2025 Earnings Guidance - MarketBeat
Haemonetics earnings beat by $0.02, revenue fell short of estimates - Investing.com
Haemonetics Corp Q3 Earnings: EPS at $0.74 Misses Estimates, Rev - GuruFocus.com
Haemonetics: Fiscal Q3 Earnings Snapshot -February 06, 2025 at 06:40 am EST - Marketscreener.com
Haemonetics Corp Reports Q3 Revenue Of $348.5 Million, Up 3.7% YoY -February 06, 2025 at 06:29 am EST - Marketscreener.com
Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates - Yahoo Finance
Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website - Quantisnow
Haemonetics (HAE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Haemonetics (NYSE:HAE) Reaches New 12-Month LowWhat's Next? - MarketBeat
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow - Barchart
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow By Stock Story - Investing.com Canada
Haemonetics FY2027 EPS Forecast Reduced by Zacks Research - MarketBeat
Haemonetics Corp (HAE) Q3 2025 Earnings Report Preview: What To Look For - GuruFocus.com
Short Interest in Haemonetics Co. (NYSE:HAE) Expands By 6.5% - MarketBeat
Q3 EPS Estimates for Haemonetics Lowered by Zacks Research - MarketBeat
FY2025 EPS Estimates for Haemonetics Lowered by Analyst - MarketBeat
Zacks Research Forecasts Reduced Earnings for Haemonetics - Defense World
Haemonetics (NYSE:HAE) Sets New 1-Year LowTime to Sell? - MarketBeat
How Is The Market Feeling About Haemonetics? - Benzinga
Global Blood Bank Management Software Market Size, Share - openPR
Oversold Conditions For Haemonetics (HAE) - Nasdaq
Haemonetics stock touches 52-week low at $69.2 amid challenges - Investing.com
Crossmark Global Holdings Inc. Sells 630 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Here's Why Haemonetics (HAE) is a Strong Value Stock - MSN
Fort Washington Investment Advisors Inc. OH Sells 35,220 Shares of Haemonetics Co. (NYSE:HAE) - MarketBeat
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock - MSN
Haemonetics stock hits 52-week low at $70.1 amid challenges - MSN
Haemonetics (NYSE:HAE) Reaches New 1-Year LowHere's Why - MarketBeat
Haemonetics stock hits 52-week low at $70.1 amid challenges By Investing.com - Investing.com Australia
Haemonetics (NYSE:HAE) Shares Down 3.2%Here's What Happened - MarketBeat
Haemonetics Co. (NYSE:HAE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Haemonetics Completes $67.8 Million Sale of Whole Blood Assets to GVS – Market - HPBL
Haemonetics Sells Whole Blood Assets to GVS for $67.8M, Focuses on Core Apheresis Business - StockTitan
Haemonetics Sets Q3 FY2025 Earnings Call for February 6Financial Results Preview - StockTitan
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term - Yahoo Finance
Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Haemonetics Co. (NYSE:HAE) Short Interest Up 7.4% in December - MarketBeat
Principal Financial Group Inc. Sells 37,433 Shares of Haemonetics Co. (NYSE:HAE) - MarketBeat
Principal Financial Group Inc. Has $12.48 Million Holdings in Haemonetics Co. (NYSE:HAE) - Defense World
HighTower Advisors LLC Sells 556 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Here's Why You Should Add HAE Stock to Your Portfolio Now - Yahoo Finance
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
8.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):